Translational Research
Here below, you will find a list of all the latest content published on this website on the topic of Translational Research. The content is published in chronological order. Find out more about our content categorisation .
-
« Previous
- 1
- 2
- ...
- 112
-
Next »
- Potential biomarkers for MPM in asbestos-exposed subjects
- Sequencing systemic therapy without driver mutations
- Sequencing systemic therapy with driver mutations
- Do we need a molecular board in our hospital?
- Facts and myths of liquid biopsy
- Biomarkers for I-O
- Role of biomarkers in resistance
- Yes
- No
- Cell-based I-O in NSCLC (TIL, TCRs, CARs, NK): Is there a role?
- Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with...
- EPAC-Lung: Pooled Analysis of Circulating Tumor Cells in Advanced Non-Small Cell Lung Cancer
- Biomarkers in 1L metastatic NSCLC beyond the PD-L1: A case report
- Activity of larotrectinib in TRK fusion lung cancer
- Entrectinib in NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Integrated Analysis of Patients (pts) Enrolled in STARTRK-2, STARTRK-1 and...
- Comprehensive profiling of genomic and TCR repertoire in localized stage lung adenocarcinomas from a prospective cohort study
- Can a BALF profile distinguish hot vs. cold lung tumors?
- Implementation of Artificial Intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center
- NSCLC stages IIa - IIIc : Tumor related IGRT yields better local control than kV-guidance to anatomic structures
- Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non small cell lung cancer (NSCLC)
- Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent Non-Small Cell Lung Cancer.
- Dynamic changes of patelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC
- Monitoring of blood Serum Amyloid (SAA) to predict outcome of first-line Pembrolizumab (P) in patients (pts) with Advanced Non-Small-Cell Lung Canc...
- Initial Serum Tumor Marker Dynamics Predict Progression-free and Overall Survival in Single PD-1/PD-L1 Inhibitor Treated Advanced NSCLC
- Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients.
-
« Previous
- 1
- 2
- ...
- 112
-
Next »